1
Published 2018
Canadian Agency for Drugs and Technologies in Health
... intolerant to one or more conventional DMARDs. BSC was defined as conventional DMARDs, which included...

2
Published 2018
Canadian Agency for Drugs and Technologies in Health
... intolerant to one or more conventional DMARDs. BSC was defined as conventional DMARDs, which included...

5
Published 2019
Canadian Agency for Drugs and Technologies in Health
... inadequately to one or more DMARDs, if the following conditions are met : Conditions for Reimbursement...

6
Published 2019
Canadian Agency for Drugs and Technologies in Health
... inadequately to one or more DMARDs, if the following conditions are met : Conditions for Reimbursement...

7
by Chao, Yi-Sheng, Visintini, Sarah
Published 2018
CADTH
... less effective and fail to maintain disease remission. In these cases, dose intensification or more...

8
Published 2017
Canadian Agency for Drugs and Technologies in Health

9
Published 2017
Canadian Agency for Drugs and Technologies in Health

10
by Chao, Yi-Sheng, Visintini, Sarah
Published 2018
CADTH
... less effective and fail to maintain disease remission. In these cases, dose intensification or more...

11
Published 2014
Canadian Agency for Drugs and Technologies in Health
.... Weight and nutrition can be managed by eating more protein, eating more calories, drinking more water...

12
Published 2014
Canadian Agency for Drugs and Technologies in Health
.... Weight and nutrition can be managed by eating more protein, eating more calories, drinking more water...

13
by Singh, Kavita, Argáez, Charlene
Published 2018
Canadian Agency for Drugs and Technologies in Health
...The biologic agents are a more recent introduction to the management strategy for psoriasis...

14
Published 2020
Canadian Agency for Drugs and Technologies in Health
... tazarotene (TAZ) 0.045% w/w as monotherapy in patients with more mild plaque psoriasis could be generalized...

15
Published 2012
Canadian Agency for Drugs and Technologies in Health
.... Are there sub-populations of AF patients that would benefit more from using NOACs compared to warfarin?2....

16
Published 2012
Canadian Agency for Drugs and Technologies in Health
.... Are there sub-populations of AF patients that would benefit more from using NOACs compared to warfarin?2....

17
Published 2015
Canadian Agency for Drugs and Technologies in Health

18
by Singh, Kavita, Argáez, Charlene
Published 2018
Canadian Agency for Drugs and Technologies in Health
...The biologic agents are a more recent introduction to the management strategy for psoriasis...

19
Published 2011
Canadian Agency for Drugs and Technologies in Health
... with short-acting formulations, long-acting formulations are given less frequently, but are more expensive...

20
Published 2015
Canadian Agency for Drugs and Technologies in Health
... heterogeneous class of medications known as muscle relaxants., More specifically, it is classified as an anti...